Core Insights - The Chinese nanosphere industry is experiencing rapid growth, with a projected market size of approximately 4.236 billion yuan in 2024, representing a year-on-year increase of 5.40% [2][11] - Nanospheres are critical materials in high-tech products, serving as essential components in biomedicine and flat panel displays, thus being referred to as "behind-the-scenes heroes" and "bottleneck" materials [2][11] Industry Overview - Nanospheres are micron-sized spheres with nanometer-scale pore structures, characterized by high specific surface area and unique physicochemical properties, widely used in drug delivery, LCD displays, bioseparation, medical diagnostics, and optoelectronic materials [2] - They can be classified into natural biomaterials (e.g., chitosan, collagen) and synthetic polymers (e.g., PLGA, PVA) [4] Preparation Methods - Nanospheres can be prepared using various methods, including ionic crosslinking, emulsification-solvent evaporation, and microfluidic technology, each with distinct principles, applicable materials, and performance characteristics [5][7] - Ionic crosslinking is suitable for natural biomaterials and emphasizes biocompatibility, while emulsification-solvent evaporation is widely used for synthetic polymers, and microfluidic technology allows for precise control of droplet formation [7] Industry Chain - The upstream of the nanosphere industry includes raw materials such as chitosan, starch, cellulose, and various synthetic polymers, along with production equipment like high-pressure homogenizers and laser particle size analyzers [8][9] - The midstream involves the manufacturing of nanospheres, while the downstream applications include drug delivery, biopurification, in vitro diagnostics, LCD spacers, and conductive materials [8] Market Size - The market for nanospheres in China is projected to grow significantly, with the biomedicine sector utilizing uniform-sized, surface-modifiable nanospheres for high-end drug development and precise diagnostics [11]

Core Viewpoint - The rapid development of the biopharmaceutical industry has led to increased emphasis on downstream purification technologies, making separation and purification a key focus in biopharmaceutical R&D and production [2] Industry Summary - The biopharmaceutical industry is experiencing significant growth, with increased investment in R&D and a faster pace of new product launches, resulting in heightened market competition [2] - There is a pressing demand for high-performance, stable, and reasonably priced domestic separation and purification materials due to the cost and supply pressures faced by biopharmaceutical manufacturers [2] Company Summary - The company has evolved into a leading supplier of domestic chromatography fillers and chromatography media, with a comprehensive range of products and a high market share, thanks to over a decade of cross-disciplinary R&D innovation and product accumulation [2] - The company offers a full series of self-innovated products, including polymer reverse phase, ion exchange, hydrophobic chromatography, and silica gel reverse phase, and has established a wealth of application cases and significant sales revenue in the insulin and peptide drug application areas [2]

证券日报网讯1月20日，纳微科技在互动平台回答投资者提问时表示，高性能微球在半导体领域有化学 机械拋光、先进封装、导电互连等应用场景。公司目前专注于生物医药、分析检测、体外诊断和平板显 示领域的核心微球材料供应及相关技术服务，尚无半导体领域的业务收入。 ...

Summary of Nanwei Technology Conference Call Company Overview - **Company Name**: Nanwei Technology - **Industry Focus**: Chromatography fillers and chromatography media, primarily used in the purification of drugs such as antibodies, nucleic acids, and recombinant proteins, which account for over 65% of the consumable costs in drug production [2][8] Key Financial Projections - **2025 Revenue Growth**: Expected overall revenue growth of 18% [2][6] - **Chromatography Fillers and Media**: Approximately 60% of total revenue, with a growth rate of about 20% [2][6] - **Analytical Instruments**: Approximately 20% of total revenue, with a growth rate of about 10% [2][6] - **Chromatography Columns**: Slightly over 10% of total revenue, with a growth rate of 30-40% [2][6] Market Analysis - **Domestic Market Size**: The domestic chromatography fillers and media market is approximately 6 billion RMB, with domestic brands holding nearly 30% market share [2][9] - **Leading Domestic Brands**: Nanwei Technology, Boge Long, and Saifen are in the first tier, while foreign brands dominate with over 70% market share [9][10] - **Overseas Market Size**: Estimated at 30 billion RMB, five times larger than the domestic market, with significant growth potential for domestic leaders like Nanwei Technology [2][11] - **Chromatography Column Market**: The domestic market is about 1.5 billion RMB, with Nanwei Technology being the largest domestic brand, but with substantial room for growth compared to the 13 billion RMB overseas market [2][13] Business Performance - **Revenue Breakdown**: - Domestic revenue accounts for 90% with a year-on-year growth of 15.5% [3][7] - International revenue accounts for 10% with a year-on-year growth of 123.1%, primarily from core chromatography fillers and media [3][7] - **Acquisition of Fuli Instruments**: Nanwei Technology acquired Fuli Instruments, which produces gas and liquid chromatography instruments, with plans for future growth in this segment [2][14] Product Development and Innovation - **Product Evolution**: - Founded in 2007, initially focused on optoelectronic devices, shifted to pharmaceuticals in 2012, and has since developed various chromatography products [4] - Recent product launches include polymer affinity fillers in 2019 and agarose affinity fillers in 2023 [4] - **Future Product Potential**: The new L75 liquid chromatography instrument from Fuli Instruments is expected to gain traction in the market [14] Competitive Landscape - **Domestic Competition**: The domestic chromatography media market is characterized by significant competition from both domestic and foreign brands, with a trend towards increased market share for domestic brands due to cost advantages [10] - **International Expansion**: Despite the large overseas market, domestic companies like Nanwei Technology are still in the early stages of development abroad, indicating substantial growth opportunities [11] Subsidiary Performance - **Nanpu Analysis**: Revenue of 47.1 million RMB with a net profit of 9.8 million RMB [15] - **Saipu Instruments**: Focused on large molecule separation and purification equipment, with revenue of 25.8 million RMB but a net loss of 220,000 RMB [15] - **Overall Assessment**: Various business segments are in phases of rapid growth or adjustment, with some new products requiring time to mature for higher sales [15]

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.84% on January 16, with Sunflower leading the drop [1] - The Shanghai Composite Index closed at 4101.91, down 0.26%, while the Shenzhen Component Index closed at 14281.08, down 0.18% [1] Top Performers - Rundu Co., Ltd. (002923) saw a closing price of 13.95, with an increase of 6.98% and a trading volume of 202,900 shares, amounting to a transaction value of 282 million yuan [1] - Qijian Technology (605116) closed at 34.43, up 6.04%, with a trading volume of 69,200 shares and a transaction value of 234 million yuan [1] - Dize Pharmaceutical (688192) closed at 67.89, increasing by 4.45% with a trading volume of 50,400 shares and a transaction value of 343 million yuan [1] Underperformers - Sunflower (300111) closed at 4.07, down 17.94%, with a trading volume of 2,495,800 shares and a transaction value of 1.028 billion yuan [2] - Nawei Technology (688690) closed at 27.09, down 8.29%, with a trading volume of 219,700 shares and a transaction value of 607 million yuan [2] - Shanhe Pharmaceutical Auxiliary (300452) closed at 15.54, down 7.77%, with a trading volume of 500,000 shares and a transaction value of 780 million yuan [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.134 billion yuan from institutional investors, while retail investors had a net inflow of 1.006 billion yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Maiwei Biological (688062) had a net inflow of 44.98 million yuan from institutional investors, while retail investors experienced a net outflow of 59.57 million yuan [3] - Xingqi Eye Medicine (300573) saw a net inflow of 43.26 million yuan from institutional investors, with retail investors facing a net outflow of 66.17 million yuan [3] - Fuxiang Pharmaceutical (300497) had a net inflow of 42.70 million yuan from institutional investors, while retail investors had a net outflow of 53.80 million yuan [3]

Group 1 - Huasheng Tiancheng's AI-related revenue currently accounts for a low proportion of overall revenue, indicating that it does not significantly impact the company's performance [2] - CICC's merger with Dongxing Securities and Xinda Securities is still undergoing audit work, which has not yet been completed [2] - Xinhua Department Store confirmed that there are no undisclosed major matters related to semiconductor asset injections, addressing market rumors [3] Group 2 - Zhong Rare Metals signed a strategic cooperation agreement with Xian Dao Group to enhance market share and industry influence in rare metals [4] - Zhongtian Rocket reported losses in its carbon/carbon thermal field materials business due to intensified competition in the photovoltaic industry [5] - Zhongyuan Nepe proposed to acquire 59% of Zhongyuan Jikean's equity for 143 million yuan, which will make it a wholly-owned subsidiary [5] Group 3 - Jiangxi Copper's subsidiary signed a cooperation agreement with First Quantum Minerals for exploration projects [6] - China Nuclear Power's Jiangsu Xuwei Nuclear Energy Heating Power Plant's first unit is set to pour its first concrete on January 16, 2026 [6] - ST Aowei's stock may be delisted if it continues to trade below par value [6] Group 4 - Triangle Tire plans to invest 3.219 billion yuan in a new high-performance tire project in Cambodia, expected to generate annual revenue of 2.585 billion yuan [7] - Baoxin Technology intends to publicly sell part of its subsidiary's assets, with a valuation of 50.2334 million yuan [7] - Nong Shang Environment's computing infrastructure project has not progressed as planned due to funding issues [8] Group 5 - Golden Dragon Fish plans to transfer stakes in two subsidiaries to Mars China for a total of 60 million USD, which is expected to impact its 2026 earnings significantly [8] - Jin Dao Technology intends to issue convertible bonds to raise up to 306 million yuan for various projects [8] - Aerospace Information expects a net loss of 700 million to 980 million yuan for 2025 due to industry changes [10] Group 6 - Tianji Co. forecasts a net profit of 70 million to 105 million yuan for 2025, recovering from a previous loss [10] - Muyuan Foods anticipates a net profit decrease of 12.2% to 17.79% for 2025 [11] - SAIC Group expects a net profit increase of 438% to 558% for 2025, driven by sales growth [12] Group 7 - Haolaike expects a significant drop in net profit for 2025, projecting a decrease of 75.16% to 83.23% [13] - Hainan Development anticipates a net loss of 440 million to 565 million yuan for 2025 [13] - Shuangliang Energy expects to report a loss for 2025 [14] Group 8 - Aijian Group also anticipates a loss for 2025 [14] - Meijin Energy forecasts a net loss of 850 million to 1.25 billion yuan for 2025 [14] - Kunlun Wanwei expects to report a loss for 2025 [14] Group 9 - Xue Rong Biological expects a net profit of 29 million to 40 million yuan for 2025, recovering from a previous loss [15] - Xin Nuo Wei anticipates a net loss of 170 million to 255 million yuan for 2025 due to increased R&D expenses [15] - Shengnuo Biological expects a net profit increase of 204.42% to 280.53% for 2025 [16] Group 10 - Longyuan Construction forecasts a net loss of 1 billion to 1.5 billion yuan for 2025 [17] - Kosen Technology expects a net loss of 245 million to 330 million yuan for 2025 [17] - Daqian Ecology anticipates a net loss of 100 million to 120 million yuan for 2025 [17] Group 11 - Lianfa Co. expects a net profit increase of 38.92% to 58.77% for 2025 [18] - Chongqing Steel anticipates a net loss of 2.5 billion to 2.8 billion yuan for 2025, but expects to reduce losses compared to the previous year [18] - Tongxing Technology forecasts a net profit increase of 74.2% to 125.44% for 2025 [19] Group 12 - Siyuan Electric expects a net profit of 3.163 billion yuan for 2025, a 54.35% increase year-on-year [19] - Luoyang Molybdenum expects a net profit increase of 47.8% to 53.71% for 2025 [20] - Nawei Technology anticipates a net profit increase of 54.51% to 75.03% for 2025 [20] Group 13 - Jingjia Micro expects a net loss of 120 million to 180 million yuan for 2025 [21] - Southwest Securities forecasts a net profit increase of 47% to 57% for 2025 [22] - Wankai New Materials expects a net profit of 156 million to 203 million yuan for 2025, recovering from a previous loss [22] Group 14 - Yilian Network anticipates a slight decrease in net profit for 2025, projecting a decline of 0% to 4% [23] - Baofeng Energy expects a net profit increase of 73.57% to 89.34% for 2025 [23] - Sanmei Co. forecasts a net profit increase of 155.66% to 176.11% for 2025 [23] Group 15 - Zhenyu Technology expects a net profit increase of 96.89% to 116.58% for 2025 [24] - Fute Technology anticipates a net profit increase of 121.98% to 164.26% for 2025 [24] - Guoli Electronics expects a net profit increase of 124.89% to 164.57% for 2025 [24] Group 16 - Shenyu Co. expects a slight decrease in net profit for 2025, projecting a decline of 0.05% to 11.37% [25] - Rongchang Biological plans to increase its share repurchase price limit to 116 yuan per share [26] - Defu Technology plans to repurchase shares for 75 million to 150 million yuan [26] Group 17 - ST Chengchang's stock will resume trading on January 16 after completing a trading fluctuation investigation [27] - Zhi Te New Materials will also resume trading on January 16 after confirming no major changes in business operations [27] - Lio Co. will suspend trading starting January 16 for stock fluctuation investigation [27]

证券日报网讯 1月15日，纳微科技发布公告称，公司预计2025年年度实现营业收入9.18亿元至9.30亿 元，同比增长17.32%至18.86%；预计实现归属于母公司所有者的净利润1.28亿元至1.45亿元，同比增长 54.51%至75.03%。 （文章来源：证券日报） ...

新京报贝壳财经讯1月15日，纳微科技公告，预计2025年年度实现归属于母公司所有者的净利润1.28亿 元至1.45亿元，较上年度(法定披露数据)相比，将增加0.45亿元至0.62亿元，同比增长54.51%至 75.03%。预计2025年年度实现营业收入9.18亿元至9.3亿元，较上年度(法定披露数据)相比，将增加1.36 亿元至1.48亿元，同比增长17.32%至18.86%。预计2025年年度实现扣除非经常性损益后归属母公司所有 者的净利润1.12亿元至1.28亿元，较上年度(法定披露数据)相比，将增加0.46亿元至0.62亿元，同比增长 70.02%至94.31%。 ...

Group 1 - Siyuan Electric reported a total operating revenue of 21.205 billion yuan for 2025, a year-on-year increase of 37.18%, with a net profit attributable to shareholders of 3.163 billion yuan, up 54.35% year-on-year [1] - VisiOn expects a negative net profit for 2025, indicating a loss in operating performance [2] - Chongqing Steel anticipates a net loss of 2.5 billion to 2.8 billion yuan for 2025, which is an improvement from a net loss of 3.196 billion yuan in the previous year [3] - Lianfa Co. forecasts a net profit of 280 million to 320 million yuan for 2025, representing a year-on-year growth of 38.92% to 58.77% [4] Group 2 - CICC announced that the audit work related to the absorption merger with Dongxing Securities and Xinda Securities has not yet been completed [5] - Dalong Real Estate's subsidiary won a project bid worth 763 million yuan [6] - Zhongchuang Zhiling plans to issue convertible bonds to raise no more than 4.35 billion yuan for various projects [7] - Jintong Co. intends to acquire a 24% stake in Jinsha Molybdenum for 1.731 billion yuan [8] Group 3 - Nami Technology expects a net profit of 128 million to 145 million yuan for 2025, an increase of 54.51% to 75.03% year-on-year [9] - China State Construction reported a new contract total of 4.5458 trillion yuan for 2025, a 1% increase year-on-year [12] - China Metallurgical Group's new contract amount for 2025 is expected to decrease by 10.8% to 1.1136 trillion yuan [13] Group 4 - Beiding Co. reported a net profit of 111 million yuan for 2025, a year-on-year increase of 59.05% [14] - Southwest Securities expects a net profit of 1.028 billion to 1.098 billion yuan for 2025, an increase of 47% to 57% [15] - China Eastern Airlines reported a 4.93% year-on-year increase in passenger capacity for December 2025 [20] Group 5 - *ST Aowei's stock may be delisted due to a closing price below par value [21] - Yilian Network expects a net profit of 2.542 billion to 2.648 billion yuan for 2025, a decrease of 0% to 4% year-on-year [22] - Huochen Co. anticipates a net profit of 420 million to 540 million yuan for 2025, recovering from a loss of 2 million yuan in the previous year [17] Group 6 - Guoli Electronics expects a net profit of 68 million to 80 million yuan for 2025, an increase of 124.89% to 164.57% [28] - Jinchuan Group forecasts a net profit of 11 billion to 12 billion yuan for 2025, a year-on-year increase of 73.57% to 89.34% [41] - Triangle Tire plans to invest 3.219 billion yuan in a new tire project in Cambodia [42]

Core Viewpoint - Nanwei Technology expects a significant increase in net profit for 2025, projecting a growth of 54.51% to 75.03% year-on-year, driven by strategic market development and product innovation [1] Financial Performance - The company forecasts a net profit attributable to shareholders of 128 million to 145 million yuan for 2025 [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 112 million and 128 million yuan, reflecting a year-on-year increase of 70.02% to 94.31% [1] Business Strategy - The company is implementing a "3+2" market development strategy focusing on three key sectors: peptides, bispecific antibodies/ADC, and blood products, while also exploring growth opportunities in vaccines and small nucleic acids [1] - The strategy aims to enhance competitive advantages through technological innovation of key products and quality improvements [1] Sales Growth - Sales revenue from core products, including chromatographic fillers and chromatography media, has increased by approximately 23% this year [1] - Sales revenue from liquid chromatography columns and sample preparation products has seen a growth of about 32% [1] International Expansion - The company is intensifying efforts to expand into international markets, enhancing its overseas marketing system and strengthening sales capabilities [1] - International business revenue reached approximately 84 million yuan, marking a year-on-year increase of about 79% [1]